226 filings
Page 2 of 12
S-8 POS
8laoz1
28 Mar 23
Registration of securities for employees (post-effective amendment)
4:30pm
25
e41itxts
27 Mar 23
Voluntary exchange delisting
4:20pm
8-K
ocbvn9rx
22 Mar 23
Other Events
5:23pm
8-K
ku7c0n8p3i4
15 Mar 23
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
7:30am
8-K
3n53u1
13 Mar 23
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
7:05am
8-K
a54opgqphut71mi
1 Mar 23
Entry into a Material Definitive Agreement
8:30am
8-K
yep9no
24 Feb 23
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
9:26am
8-K
n5tw2am94l f3jt0
3 Jan 23
Regulation FD Disclosure
8:00am
6-K
z6swmvhcv oqr4v
19 Dec 22
ObsEva Announces Dismissal of Moratorium Proceedings
8:30am
6-K
pcctcgyigx
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
EFFECT
hrc3fo kt2xd
13 Dec 22
Notice of effectiveness
12:15am
6-K
5imsr1iym510f7bhyym0
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
F-3
7uk21ct5
9 Dec 22
Shelf registration (foreign)
7:06am
CORRESP
bysaqt3hupdp5xtj
9 Dec 22
Correspondence with SEC
12:00am
UPLOAD
iszzmfei eqqmw01l42
9 Dec 22
Letter from SEC
12:00am
6-K
weqi tgnm32ill8igf8
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
ryzos
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
twghfcqn
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
tvp61zx 0rpjf5
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
r2boa76qjuz4 bk
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am